For instance, phase 2B clinical trial studies showed that the GLP-1 agonist liraglutide reduced brain atrophy in regions involved in memory and decision-making by nearly 50% compared to the placebo [130,131]. The gene discussed is GLP1R; the disease is Brain atrophy.